Tag
Michael Polansky’s Outer Bio launched with $23M and an unusual pitch: not a drug company, but an AI platform screening compounds on living human skin.
The Tokyo AI firm and Julien Orts’s NMR lab will combine machine learning with atomic-resolution spectroscopy to target intrinsically disordered proteins in cancer.
By testing half a million DNA variants, researchers pinned down the signature of the “initiator” — the element that marks where a gene is switched on — and found it in roughly 60% of human genes.
From a whole-genome map built on over a trillion lab-grown neurons, the partners pinpointed a novel neuro target in 15 months — the first payoff from a collaboration worth up to $12 billion.
The AI-first primary-care startup adds Summer Health’s text-based pediatric service and a 100,000-message dataset to cover care ‘from birth through adulthood.’